Latest Conference Articles

The 2011 European Multidisciplinary Cancer Congress Slideshow

Pictures from The 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden

Synchronous Radiotherapy With Chemotherapy Improves Local Control in Early Breast Cancer Patients

Radiotherapy can be given between or during chemotherapy cycles, rather than sequentially, for women with early breast cancer.

Aflibercept Improves Survival in Metastatic Colorectal Cancer Patients

Aflibercept added to FOLFIRI chemotherapy improved PFS and OS in previously treated patients with metastatic colorectal cancer.

T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast Cancer

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

Panitumumab Extends Progression-Free Survival in HPV-Negative Subset of Advanced Head and Neck Cancer

Panitumumab + chemo improves OS and PFS in patients with metastatic carcinoma of the head and neck that were negative for HPV.

Survival Benefit Shown With Investigational Alpha-Emitting Radiopharmaceutical in Men With Hormone Resistant Metastatic Prostate Cancer

Investigational drug that emits alpha radiation shows significant improvement in overall survival.

Novel Infusion Approach Significantly Delays Progression in Uveal Melanoma Patients With Liver Metastases

Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).

Two Predictors of Prostate Cancer Explored in Healthy Men

Two studies enhance understanding of risk factors for prostate cancer.

Image of Stockholm City Hall

The 16th ECCO, 36th ESMO, 30th ESTRO Congresses from the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23-27.

ASCO 2011 Annual Meeting Daily Picture Slideshows

American Society of Clinical Oncology (ASCO) 2011 Annual Meeting Daily Picture Slideshow

Updated Cabozantinib Data Includes 6 Patient Deaths

Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial.

Dr. Vogelzang on Mortalities in the Cabozantinib Trial

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.

Post-Oophorectomy Hormone Replacement Therapy Safe for BRCA1/2 Mutation Carriers

Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.

Dr. Infante Talks About BRAF Mutation Testing

Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing

PTEN Expression Does Not Diminish Trastuzumab Effectiveness

Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer

ASCO 2011 Annual Meeting Picture Slideshow Day Four

American Society of Clinical Oncology 2011 Annual Meeting Picture Slideshow Day Four

Axitinib Outperforms Sorafenib in Renal Cell Carcinoma Trial

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib

Deciphering the Challenge of the Genomic Era in Breast Cancer

Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate

Rethinking Initial Management of Patients With Brain Metastasis and HER2 Breast Cancer

Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer

Two Studies Herald New Era in Melanoma Therapy

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Three-Year Imatinib Regimen Delivers Optimal GIST Treatment

3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival

Pemetrexed Maintenance Improves Progression-Free Survival in Patients With NSCLC

Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer

Dr. Wolchok Describes the Immunotherapy Ipilimumab

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Dr. Kris on the Use of Genetic Testing in Lung Cancer

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

MEK and BRAF Therapy Combo Promising for Advanced Melanoma

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Virgo on Survivorship Care Training & Policies

Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies

Dr. Hoos on the Patients That Respond to Ipilimumab

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Chapman Describes the Side Effects of Vemurafenib

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Dr. Tsimberidou Discusses Improving Care

Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.

Dr. Cella on Patient Assessment Reference Scores

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores